ATE397609T1 - Corticotropinfreisetzungsfaktor antagonisten - Google Patents

Corticotropinfreisetzungsfaktor antagonisten

Info

Publication number
ATE397609T1
ATE397609T1 AT02730487T AT02730487T ATE397609T1 AT E397609 T1 ATE397609 T1 AT E397609T1 AT 02730487 T AT02730487 T AT 02730487T AT 02730487 T AT02730487 T AT 02730487T AT E397609 T1 ATE397609 T1 AT E397609T1
Authority
AT
Austria
Prior art keywords
alkyl
halo
alkoxy
alkenyl
alkynyl
Prior art date
Application number
AT02730487T
Other languages
English (en)
Inventor
Fabio Romano Di
Chiara Marchionni
Fabrizio Micheli
Alessandra Pasquarello
Benedetta Perini
Yves St-Denis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0114343A external-priority patent/GB0114343D0/en
Priority claimed from GB0114349A external-priority patent/GB0114349D0/en
Priority claimed from GB0117399A external-priority patent/GB0117399D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE397609T1 publication Critical patent/ATE397609T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02730487T 2001-06-12 2002-06-11 Corticotropinfreisetzungsfaktor antagonisten ATE397609T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0114343A GB0114343D0 (en) 2001-06-12 2001-06-12 Chemical compounds
GB0114349A GB0114349D0 (en) 2001-06-12 2001-06-12 Chemical compounds
GB0117399A GB0117399D0 (en) 2001-07-17 2001-07-17 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE397609T1 true ATE397609T1 (de) 2008-06-15

Family

ID=27256186

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02730487T ATE397609T1 (de) 2001-06-12 2002-06-11 Corticotropinfreisetzungsfaktor antagonisten

Country Status (7)

Country Link
US (1) US7462622B2 (de)
EP (1) EP1395591B1 (de)
JP (1) JP2004533465A (de)
AT (1) ATE397609T1 (de)
DE (1) DE60226971D1 (de)
ES (1) ES2307750T3 (de)
WO (1) WO2002100863A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CN100372851C (zh) * 2003-05-05 2008-03-05 弗·哈夫曼-拉罗切有限公司 具有crf活性的稠合的嘧啶衍生物
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
CN1926140A (zh) * 2004-03-05 2007-03-07 大正制药株式会社 吡咯并嘧啶衍生物
ATE430746T1 (de) * 2004-10-19 2009-05-15 Smithkline Beecham Cork Ltd Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
WO2019198692A1 (en) * 2018-04-09 2019-10-17 Raqualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022644D0 (en) 1990-10-18 1990-11-28 Ici Plc Heterocyclic compounds
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
IL134748A0 (en) 1997-09-02 2001-04-30 Du Pont Pharm Co Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
AR033295A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ES2307750T3 (es) 2008-12-01
JP2004533465A (ja) 2004-11-04
US20050054661A1 (en) 2005-03-10
US7462622B2 (en) 2008-12-09
DE60226971D1 (de) 2008-07-17
EP1395591B1 (de) 2008-06-04
WO2002100863A1 (en) 2002-12-19
EP1395591A1 (de) 2004-03-10

Similar Documents

Publication Publication Date Title
MXPA05010874A (es) Compuestos n-heterociclicos condensados y su uso como antagonistas del receptor del factor liberador de corticotropina.
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
ZA200505273B (en) Novel compound
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
WO2003008412A3 (en) Hetero-bicyclic crf antagonists
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
ATE397609T1 (de) Corticotropinfreisetzungsfaktor antagonisten
UA85502C2 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
RS44004A (en) Processes for the preparation of substituted bicyclid derivatives for the treatment of abnormal cell growth
AP1396A (en) 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
ZA200309942B (en) Chemical compounds.
GEP20032928B (en) Halo Derivatives of 9-Deoxo-9a-Aza-9a-Homerythromycin A, Method for its Production, Pharmaceutical Compositions Containing the Same and Their Use for Treatment or Prevention of Bacterial Infections
HK1075656A1 (en) New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
ATE238995T1 (de) $g(a)-$g(a)' -substituierte n-alkyl-3- alkenylbenzoyl-pyrazol-derivate
YU79401A (sh) Derivati 1-trifluorometil-4-hidroksi-7-piperidinil- aminometilhromana

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties